Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: A possible compensatory mechanism

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 10, 2012, Pages 823-830

  Bertolotti, M ^a   Del Puppo, M ^b   Corna, F ^b   Anzivino, C ^a   Gabbi, C ^a   Baldelli, E ^a   Carulli, L ^a   Loria, P ^a   Galli Kienle, M ^b   Carulli, N ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Atherosclerosis; Bile acid synthesis; Cholesterol metabolism; Hypercholesterolemia; Lipid lowering drugs

Indexed keywords

26 HYDROXYCHOLESTEROL; 27-HYDROXYCHOLESTEROL; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HYDROXYLATION; HYPERCHOLESTEROLEMIA; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; FLUOROBENZENES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPTANOIC ACIDS; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYLATION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 80053279342     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.02.009     Document Type: Article

References (38)

1. Bertolotti M., Gabbi C., Anzivino C., Carulli L., Loria P., Carulli N. Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insight from evidence on hepatic cholesterol degradation and gallstone disease in humans. Curr Med Chem 2008, 15:2271-2284.
2. Hylemon P.B., Zhou H., Pandak W.M., Ren S., Gil G., Dent P. Bile acids as regulatory molecules. J Lipid Res 2009, 50:1509-1520.
3. Chiang J.Y. Bile acids: regulation of synthesis. J Lipid Res 2009, 50:1955-1966.
4. Bertolotti M., Abate N., Loria P., Dilengite M., Carubbi F., Pinetti A., et al. Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7α-hydroxylation rates in vivo. Hepatology 1991, 14:830-837.
5. Bertolotti M., Gabbi C., Anzivino C., Crestani M., Mitro N., Del Puppo M., et al. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest 2007, 37:501-508.
6. Javitt N.B. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J 1994, 8:1308-1311.
7. Björkhem I., Eggertsen G. Genes involved in initial steps of bile acid synthesis. Curr Opin Lipidol 2001, 12:97-103.
8. Shanahan C.M., Carpenter K.L., Cary N.R. A potential role for sterol 27-hydroxylase in atherogenesis. Atherosclerosis 2001, 154:269-276.
9. Björkhem I., Araya Z., Rudling M., Angelin B., Einarsson C., Wikvall K. Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J Biol Chem 2002, 277:26804-26807.
10. Duane W.C., Javitt N.B. 27-hydroxycholesterol: production rates in normal human subjects. J Lipid Res 1999, 40:1194-1199.
11. Lund E., Andersson O., Zhang J., Babiker A., Ahlborg G., Diczfalusy U., et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 1996, 16:208-212.
12. Weingärtner O., Laufs U., Böhm M., Lütjohann D. An alternative pathway of reverse cholesterol transport: the oxysterol 27-hydroxycholesterol. Atherosclerosis 2010, 209:39-41.
13. Bertolotti M., Concari M., Loria P., Abate N., Pinetti A., Guicciardi M.E., et al. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7α-hydroxylation in humans. Arterioscler Thromb Vasc Biol 1995, 15:1064-1069.
14. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004, 160:407-420.
15. Gaddi A., Cicero A.F., Odoo F.O., Poli A.A., Paoletti R. Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag 2007, 3:877-886.
16. Del Puppo M., Crosignani A., Longo M., Zuin M., Podda M., Galli G., et al. A minimally invasive technique for the evaluation of the regulatory steps of the two major pathways of bile acid synthesis. Clin Chim Acta 2005, 355:23-31.
17. Alessandrini L., Ciuffreda P., Santaniello E., Terraneo G. Clemmensen reduction of diosgenin and kryptogenin: synthesis of [16,16,22,22,23,23-(2)H(6)]-(25R)-26-hydroxycholesterol. Steroids 2004, 69:789-794.
18. Del Puppo M., Galli Kienle M., Petroni M.L., Crosignani A., Podda M. Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res 1998, 39:2477-2482.
19. Bertolotti M., Zambianchi L., Carulli L., Simonini M.S., Del Puppo M., Galli Kienle M., et al. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 2003, 38:939-946.
20. Babiker A., Dzeletovic S., Wiklund B., Pettersson N., Salonen J., Nyyssönen K., et al. Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 2005, 65:365-375.
21. Burkard I., von Eckardstein A., Waeber G., Vollenweider P., Rentsch K.M. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis 2007, 194:71-78.
22. Xu G., Salen G., Shefer S., Tint G.S., Nguyen L.B., Parker T.T., et al. Regulation of classic and alternative bile acid synthesis in hypercholesterolemic rabbits: effects of cholesterol feeding and bile acid depletion. J Lipid Res 1998, 39:1608-1615.
23. Angelin B. Bile acid metabolism in heterozygous familial hypercholesterolaemia: a study comparing affected and unaffected siblings of four kindreds. Eur J Clin Invest 1988, 18:153-161.
24. Damgaard D., Jensen J.M., Larsen M.L., Soerensen V.R., Jensen H.K., Gregersen N., et al. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the familial hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes. Atherosclerosis 2004, 177:415-422.
25. Einarsson K., Reihnér E., Björkhem I. On the saturation of the cholesterol 7alpha-hydroxylase in human liver microsomes. J Lipid Res 1989, 30:1477-1481.
26. Pandak W.M., Ren S., Marques D., Hall E., Redford K., Mallonee D., et al. Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes. J Biol Chem 2002, 277:48158-48164.
27. Lange Y., Steck T.L., Ye J., Lanier M.H., Molugu V., Ory D.S. Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J Lipid Res 2009, 50:1881-1888.
28. Axelson M., Larsson O. Low density lipoprotein (LDL) cholesterol is converted to 27-hydroxycholesterol in human fibroblasts. Evidence that 27-hydroxycholesterol can be an important intracellular mediator between LDL and the suppression of cholesterol production. J Biol Chem 1995, 270:15102-15110.
29. Quinn C.M., Jessup W., Wong J., Kritharides L., Brown A.J. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands. Biochem J 2005, 385:823-830.
30. Szanto A., Benko S., Szatmari I., Balint B.L., Furtos I., Rühl R., et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol Cell Biol 2004, 24:8154-8166.
31. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008, 299:1561-1573. PERISCOPE Investigators.
32. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
33. Gilardi F., Viviani B., Galmozzi A., Boraso M., Bartesaghi S., Torri A., et al. Expression of sterol 27-hydroxylase in glial cells and its regulation by liver X receptor signaling. Neuroscience 2009, 164:530-540.
34. Björkhem I. Do oxysterols control cholesterol homeostasis?. J Clin Invest 2002, 110:725-730.
35. Javitt N.B. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J Lipid Res 2002, 43:665-670.
36. Levy J., Budai K., Javitt N.B. Bile acid synthesis in HepG2 cells: effect of cyclosporin. J Lipid Res 1994, 35:1795-1800.
37. Zanotti I., Stomeo G., Zimetti F., Potì F., Bernini F. Cyclosporin A modulates the macrophage reverse cholesterol transport in vivo. Nutr Metab Cardiovasc Dis 2009, 19(Suppl. 1):S31.
38. Blom T., Bäck N., Mutka A.L., Bittman R., Li Z., de Lera A., et al. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ Res 2010, 106:720-729.